3 episodes
Immunotherapy Talks with ACIR Accelerating Cancer Immunotherapy Research (ACIR)
-
- Science
-
-
5.0 • 2 Ratings
-
Reading research can be complicated — but it doesn’t have to be. In this podcast, ACIR digests the latest in cancer immunotherapy research into bite size pieces to help you stay on top of the field. Stay tuned to hear which expert will be invited on our next episode!
-
#2 - A biomaterial-based vaccine
Send us a Text Message.
In this 2nd episode, our co-hosts discuss the use of a macro-scale material to co-deliver GMCSF and CpG, both APC stimulating agents, as well as AML antigens to kill AML cells.
GUEST: Alex Najibi is now a postdoctoral fellow at Harvard School of Engineering and Applied Sciences, studying bioengineering in David Mooney's lab.
Original study => https://pubmed.ncbi.nlm.nih.gov/31937942/
Support the Show.
Thanks for listening! Let’s stay in touch:
Tweet us at @ImmunoTalks Share our episodes on LinkedIN and Instagram Email us at contact@acir.org -
#1- Hooked on immunotherapy
Send us a Text Message.
In this first episode, our co-hosts talk about their background in immunology and what led them to it.
GUEST: Ed Fritsch. PhD, presidential fellow at the Dana-Farber, co-author of "Molecular Cloning: A Laboratory Manual", and co-founder of ACIR.
Support the Show.
Thanks for listening! Let’s stay in touch:
Tweet us at @ImmunoTalks Share our episodes on LinkedIN and Instagram Email us at contact@acir.org -
Teaser
Send us a Text Message.
Introducing "Immunotherapy Talks".
Reading research can be complicated — but it doesn’t have to be. In this podcast, ACIR digests the latest in cancer immunotherapy research into bite size pieces to help you stay on top the field.
Support the Show.
Thanks for listening! Let’s stay in touch:
Tweet us at @ImmunoTalks Share our episodes on LinkedIN and Instagram Email us at contact@acir.org